COVID-19疫情对儿童呼吸道感染病原流行病学影响

doi:10.12372/jcp.2025.24e1156

摘要/Abstract

摘要：

新型冠状病毒肺炎（COVID-19）疫情暴发后全球不同地域、不同病原体所致儿童呼吸道感染的流行病学发生了变化，我国同样也发生了类似情况，这些改变为临床儿童呼吸道感染的预防和诊治增加了很大困难。因此本文旨在总结疫情后儿童呼吸道感染不同病原体流行病学的变化，以期为该病的精准化预防和治疗提供一些思路。

关键词: 新型冠状病毒肺炎疫情, 非药物干预措施, 呼吸道感染, 儿童

Abstract:

After the outbreak of COVID-19, the epidemiology of different pathogens causing childhood respiratory infections in different geographical regions around the world has changed, and the similar changes have occurred in China. These changes have greatly increased the difficulties in preventing and treating pediatric respiratory infections in clinical practice. Therefore, this paper aims to summarize the epidemiological changes of different pathogens in children with respiratory tract infection after the epidemic, in order to provide some ideas for the precise prevention and treatment of the disease.

Key words: COVID-19 pandemic, non-pharmaceutical interventions, respiratory tract infection, child

郝创利, 蒋吴君. COVID-19疫情对儿童呼吸道感染病原流行病学影响[J]. 临床儿科杂志, 2025, 43(3): 163-167.

HAO Chuangli, JIANG Wujun. Influence of COVID-19 epidemic on the epidemiology of pathogens causing respiratory tract infections in children[J]. Journal of Clinical Pediatrics, 2025, 43(3): 163-167.

参考文献 39

[1]	Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity[J]. Nat Rev Microbiol, 2023, 21(3): 195-210.
[2]	Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data[J]. Lancet Digit Health, 2021, 3(6): e360-e370.
[3]	Cohen R, Pettoello-Mantovani M, Somekh E, et al. European pediatric societies call for an implementation of regular vaccination programs to contrast the immunity debt associated to coronavirus disease-2019 pandemic in children[J]. J Pediatr, 2022, 242: 260-261.
[4]	Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions[J]. Lancet Microbe, 2024, 5(2): e100-e101.
[5]	Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis[J]. Lancet, 2022, 399(10340): 2047-2064. doi: 10.1016/S0140-6736(22)00478-0 pmid: 35598608
[6]	Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study[J]. Lancet Infect Dis, 2023, 23(1): 56-66.
[7]	Jiang W, Chen S, Lv M, et al. Are we ready to face the next wave of RSV surge after the COVID-19 Omicron pandemic in China?[J]. Front Cell Infect Microbiol, 2023, 13: 1216536.
[8]	Bermúdez Barrezueta L, Matías Del Pozo V, López-Casillas P, et al. Variation in the seasonality of the respiratory syncytial virus during the COVID-19 pandemic[J]. Infection, 2022, 50(4): 1001-1005. doi: 10.1007/s15010-022-01794-y pmid: 35316529
[9]	Fitzpatrick T, Buchan SA, Mahant S, et al. Pediatric respiratory syncytial virus hospitalizations, 2017-2023[J]. JAMA Netw Open, 2024, 7(6): e2416077.
[10]	Laurie KL, Rockman S. Which influenza viruses will emerge following the SARS-CoV-2 pandemic?[J]. Influenza Other Respir Viruses, 2021, 15(5): 573-576.
[11]	Feng L, Zhang T, Wang Q, et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States[J]. Nat Commun, 2021, 12(1): 3249.
[12]	Li ZJ, Yu LJ, Zhang HY, et al. Broad impacts of coronavirus disease 2019 (COVID-19) pandemic on acute respiratory infections in China: an observational study[J]. Clin Infect Dis, 2022, 75(1): e1054-e1062.
[13]	Delahoy MJ, Mortenson L, Bauman L, et al. Influenza A (H3N2) outbreak on a university campus - Michigan, October-November 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(49): 1712-1714.
[14]	Huang W, Li X, Tan M, et al. Epidemiological and virological surveillance of seasonal influenza viruses - China, 2020-2021[J]. China CDC Wkly, 2021, 3(44): 918-922.
[15]	Sullivan SG, Carlson S, Cheng AC, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020[J]. Euro Surveill, 2020, 25(47): 2001847.
[16]	Takashita E, Kawakami C, Momoki T, et al. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic[J]. Influenza Other Respir Viruses, 2021, 15(4): 488-494.
[17]	Zhang RX, Chen DM, Qian Y, et al. Surges of hospital-based rhinovirus infection during the 2020 coronavirus disease-19 (COVID-19) pandemic in Beijing, China[J]. World J Pediatr, 2021, 17(6): 590-596.
[18]	Yum S, Hong K, Sohn S, et al. Trends in viral respiratory infections during COVID-19 pandemic, South Korea[J]. Emerg Infect Dis, 2021, 27(6): 1685-1688. doi: 10.3201/eid2706.210135 pmid: 34013875
[19]	Zhang K, Misra A, Kim PJ, et al. Rapid disappearance of influenza following the implementation of COVID-19 mitigation measures in Hamilton, Ontario[J]. Can Commun Dis Rep, 2021, 47(4): 202-209.
[20]	Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(29): 1013-1019.
[21]	Ippolito G, La Vecchia A, Umbrello G, et al. Disappearance of seasonal respiratory viruses in children under two years old during COVID-19 pandemic: a monocentric retrospective study in Milan, Italy[J]. Front Pediatr, 2021, 9: 721005.
[22]	Russell KL, Broderick MP, Franklin SE, et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting[J]. J Infect Dis, 2006, 194(7): 877-885. pmid: 16960774
[23]	Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease[J]. Lancet Infect Dis, 2004, 4(3): 144-154. doi: 10.1016/S1473-3099(04)00938-7 pmid: 14998500
[24]	Kajihara T, Yahara K, Kamigaki T, et al. Effects of coronavirus disease 2019 on the spread of respiratory-transmitted human-to-human bacteria[J]. J Infect, 2024, 89(2): 106201.
[25]	Choi YH, Miller E. Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling study[J]. BMJ Open, 2021, 11(9): e045380.
[26]	Ai L, Zhou C, Fang L, et al. Changes in the epidemiology and antimicrobial resistance patterns of Streptococcus pneumoniae from pediatric community acquired pneumonia patients attended in a Chinese hospital during the COVID-19 pandemic[J]. Infection, 2024. doi: 10.1007/s15010-024-02308-8.
[27]	Almeida SCG, Lemos APS, Bierrenbach AL, et al. Serotype distribution and antimicrobial susceptibility pattern of Streptococcus pneumoniae in COVID-19 pandemic era in Brazil[J]. Microorganisms, 2024, 12(2): 401.
[28]	Singer R, Abu Sin M, Tenenbaum T, et al. The increase in invasive bacterial infections with respiratory transmission in Germany, 2022/2023[J]. Dtsch Arztebl Int, 2024, 121(4): 114-120.
[29]	Meyer Sauteur PM, Beeton ML, Uldum SA, et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021[J]. Euro Surveill, 2022, 27(19): 2100746.
[30]	Meyer Sauteur PM, Chalker VJ, Berger C, et al. Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?[J]. Lancet Microbe, 2022, 3(12): e897.
[31]	Liu B, Xu L, Ma Y, et al. Evidence of immunity gap: decline in antibodies against M. pneumoniae during the COVID-19 pandemic[J]. J Infect, 2024, 89(2): 106209.
[32]	Xu L, Wang P, Wang Y, et al. Epidemiological, clinical, and genotypic characteristics of pediatric Mycoplasma pneumoniae infections: an 8-year survey in Suzhou, China in the pre- and post-COVID-19 eras[J]. Front Microbiol, 2024, 15: 1483152.
[33]	Noble BA, Jiudice SS, Jones JD, et al. Reemergence of Bordetella parapertussis, United States, 2019-2023[J]. Emerg Infect Dis, 2024, 30(5): 1058-1060.
[34]	Rumik A, Paradowska-Stankiewicz I. Pertussis in Poland in 2020[J]. Przegl Epidemiol, 2022, 76(3): 362-370. doi: 10.32394/pe.76.34 pmid: 36524879
[35]	Liu Y, Ye Q. Resurgence and the shift in the age of peak onset of pertussis in southern China[J]. J Infect, 2024, 89(2): 106194.
[36]	Hu Y, Shi W, Meng Q, et al. Detection of Bordetella spp. in children with pertussis-like illness from 2018 to 2024 in China[J]. J Infect, 2024, 89(3): 106222.
[37]	Fu P, Zhou J, Yang C, et al. Molecular evolution and increasing macrolide resistance of Bordetella pertussis, Shanghai, China, 2016-2022[J]. Emerg Infect Dis, 2023, 30(1): 29-38.
[38]	Ranasinghe L, Achar J, Gröschel MI, et al. Global impact of COVID-19 on childhood tuberculosis: an analysis of notification data[J]. Lancet Glob Health, 2022, 10(12): e1774-e1781.
[39]	Oh KH, Yanagawa M, Morishita F, et al. Changing epidemic of tuberculosis amidst the COVID-19 pandemic in the Western Pacific Region: analysis of tuberculosis case notifications and treatment outcomes from 2015 to 2022[J]. Lancet Reg Health West Pac, 2024, 47: 101104.